JAB-3312 Combination Therapy for Adults with Advanced Solid Tumors

Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04720976

Provider View

This study aims to test the safety of JAB-3312 when used with other treatments in adults with advanced solid tumors.

Patient Parameters

Program Overview

The purpose of this study is to see how safe and tolerable JAB-3312 is when given with other investigational treatments to adults who have advanced solid tumors. Researchers want to find out the best dose for future studies when JAB-3312 is combined with either a PD1 inhibitor or a MEK inhibitor.

Description

This clinical trial is designed to evaluate how safe and tolerable the drug JAB-3312 is when used in combination with other treatments for patients with advanced solid tumors. The study will help determine the best dose to use in future research when JAB-3312 is combined with a PD1 inhibitor or a MEK inhibitor. Participants will be adults who have advanced solid tumors, and the study will involve monitoring their response to the treatment to ensure it is safe and to identify any side effects.

Eligibility Criteria

Inclusion Criteria

  • Must have a confirmed diagnosis of metastatic or locally advanced solid tumor through tissue or cell analysis. Some groups may need specific gene expressions or mutations.
  • Must have organs that are functioning well enough.
  • Must have at least one tumor that can be measured according to specific guidelines.
  • Must be able to provide a stored sample of their tumor.
  • Must have a performance status score of 0 or 1, indicating they are fully active or have some restrictions but can still carry out light work.

Exclusion Criteria

  • Cannot have a history of a different type of cancer than the one being studied.
  • Cannot have active or untreated cancer spread to the brain or spinal cord.
  • Cannot have a history of lung inflammation or lung disease.
  • Cannot have active infections like hepatitis B, hepatitis C, or HIV.
  • Cannot have any severe or uncontrolled medical conditions.
  • Cannot have a heart function measurement (LVEF) of 50% or lower.
  • Cannot have a heart rhythm measurement (QTcF) greater than 470 milliseconds.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.